Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 13,600
CEO Mr. Daniel P. O'Day
Address 333 Lakeside Drive , Foster City, CA 94404
Phone 1.650.574.3000
Website www.gilead.com

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Gilead Sciences, Inc. 6.46% 13.10%
Pfizer Inc. 10.96% 28.67%
Novo Nordisk A/S 22.77% 47.76%
Thermo Fisher Scientific, Inc. 23.25% 41.55%
Danaher Corp. 21.38% 56.81%

Statement Summary

as of 4:00 ET PM 09/22/2021
Total Assets (MRQ) 68.0 B
Total Liabilities (MRQ) 48.3 B
Shareholders’ Equity (MRQ) 19.7 B
Total Revenue (Annual) 6.2 B
Net Income (Annual) 1.5 B

Earnings And Estimates

as of 4:00 ET PM 09/22/2021

Current Qtr EPS Estimate 1.69
Current FY EPS Estimate 7.13
Long Term EPS Growth Estimate 0.21
Next Expected Earnings Date //

GILD vs S&P 500

as of 09/22/2021
Relative To
S&P 500
GILD
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 09/22/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 1.74 1.87 +7.51%
03/2021 2.08 2.08 +0.09%
12/2020 2.04 2.19 +7.45%
09/2020 1.95 2.11 +8.09%
06/2020 1.44 1.11 -23.12%
03/2020 1.57 1.68 +6.73%
12/2019 1.67 1.30 -22.15%
09/2019 1.74 1.75 +0.60%

Financial Strength

as of 4:00 ET PM 09/22/2021
Pre-Tax Margin 29.12
Net Margin 0.00
Operating Margin 37.90
Return On Equity 27.36
Return On Assets 8.33
Inventory Turnover (TTM) 3.70
Sales Growth (MRQ) -5.11

Ratios

as of 4:00 PM ET 09/22/2021
Price/Earnings (TTM) 17.43
Price/Book (MRQ) 4.54
Price/Cash Flow (TTM) 9.89
Book Value (MRQ) 15.71
Quick Ratio (MRQ) 1.19
Current Ratio (MRQ) 1.36
Total Debt/Equity (MRQ) 1.53

Short Interest

as of 3:52 PM ET 09/23/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 09/22/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $1.69 $1.52
# of Estimates 20 20
High Estimate $2.00 $1.69
Low Estimate $1.47 $1.34
Year Ago EPS $0.29 $1.24
Year Over Year Growth Estimate 489.05% 23.13%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $7.13 $6.75
# of Estimates 22 22
High Estimate $7.56 $7.60
Low Estimate $6.79 $5.43
Year Ago EPS $7.09 $7.13
Year Over Year Growth Estimate 0.51% -5.21%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $1.69 $1.52 $7.13 $6.75
# of Estimates 20 20 22 22
High Estimate $2.00 $1.69 $7.56 $7.60
Low Estimate $1.47 $1.34 $6.79 $5.43
Year Ago EPS $0.29 $1.24 $7.09 $7.13
Year Over Year Growth Estimate 489.05% 23.13% 0.51% -5.21%

Insider Information Summary

as of 08/31/2021
% Insiders - 0.08%
% Remaining Total Shares - 99.92%
Current 1 Month
Net Insider Transaction 9.57 K -3.79 K
Shares Bought 29.11 K 41.02 K
Shares Sold 19.55 K 44.81 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Salesforce Lead

Stock Market Today With Jim Cramer: Sell Some Salesforce Stock

Jim Cramer discusses profit taking in Thursday's market and spillover effects from the Evergrande Capital crisis.

Evergrande Group Lead

Evergrande Quickly Fades From View

With worries about a contagious financial crisis from China easing, Wall Street shifted to the Fed and speculation, James “Rev Shark” Deporre notes.

Novavax Lead

Novavax Stock Surges on Covid-19 Vaccine Application to WHO

Novavax and Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's Covid-19 vaccine.

Why It's Unhealthy to Own Rite Aid, Plus Jim Cramer's Take

Rite Aid Stock Must Hold This Key Support Level After Dip on Earnings

Rite Aid stock has one key support level left before more potential downside. Investors trading the stock should keep that level in mind.

Cannabis Weed Marijuana Federal Lead

U.S. Cannabis Stocks Rise on Effort to Allow Bank Financing

Measure to allow banks to finance the cannabis industry passes voice vote in U.S. House.

Stock Market President's Day Lead

Dow Climbs On Fed Tapering Stance; Evergrande Debt In Focus

Stocks surge amid the Fed's patience on tapering and amid cautious optimism for a brokered solution to the Evergrande debt crisis.

Joby Aviation Lead

Air Taxi Maker Joby Aviation Rated Overweight by Morgan Stanley

Joby is 'a first mover to address the urban air mobility market,' which Morgan Stanley sees at $1 trillion in 2040 and $9 trillion in 2050.